ChemicalBook
Chinese English Japanese Germany Korea

다루나비르

다루나비르
다루나비르 구조식 이미지
카스 번호:
206361-99-1
한글명:
다루나비르
동의어(한글):
다루나비르
상품명:
Darunavir
동의어(영문):
D03656;TMC-114;UIC-94017;Darunavir;Darunavir (usan/inn);Darunavir( UIC-94017,TMC-114);Darunaviroxy-1-phenylbutan-2-yl]carbamate;(3R,3AS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3;(3R,3AS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate;(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate
CBNumber:
CB51176244
분자식:
C27H37N3O7S
포뮬러 무게:
547.66
MOL 파일:
206361-99-1.mol

다루나비르 속성

녹는점
74-760C
저장 조건
-20°C Freezer
물리적 상태
powder
색상
white to beige

안전

WGK 독일 3

다루나비르 C화학적 특성, 용도, 생산

개요

Darunavir is the latest weapon in the arsenal of agents to combat human immunodeficiency virus type 1(HIV-1). As an HIV-1 protease inhibitor, its mechanism of action involves blocking the cleavage of the gag and gag–pol polyproteins into functional proteins essential for the production of infectious progeny virus; the result is the production of immature, noninfectious viral particles. Compared to predecessor HIV protease inhibitors, darunavir retains activity against resistant stains, a critical factor with the continual emergence of multidrug- resistant (MDR) mutants. Despite experiencing a 13-fold reduction in binding to MDR HIV-1 protease, this binding is 1.5 orders of magnitude tighter than the first-generation protease inhibitors. Furthermore, darunavir exhibits less than a 10-fold decrease in susceptibility in cell culture against 90% of 3309 clinical isolates resistant to amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, and tipranavir. In contrast, darunavir-resistant viruses display limited susceptibility to only tipranavir, suggesting limited cross-resistance between these two protease inhibitors. To avoid the issues of the peptide-based protease inhibitors, darunavir has evolved from a structure-based design effort to minimize peptidic features and reduce molecular weight and complexity.

화학적 성질

White Amorphous Solid

Originator

Tibotec/J&J (US)

용도

Second generation HIV-1-protease inhibitor; structurally similar to amprenavir. Antiviral

정의

ChEBI: An N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors.

상표명

Prezista

원료

Darunavir is less affected than other protease inhibitors by mutations to resistance, but subgroups with more than 10 cumulative mutations show a >10-fold (median value) decrease in susceptibility. The major resistance mutations occur at positions 50 (150V), 54 (I50M/L), 76 (L76V) and 84 (I84V) of the protease gene.

Pharmaceutical Applications

A synthetic compound formulated as the ethanolate for oral use in combination with ritonavir.

Pharmacokinetics

Oral absorption: c. 82%
Cmax 600 mg once daily + ritonavir 100 mg twice daily: c. 6500 μg/L
Cmin 600 mg oral + ritonavir 100 mg twice daily: c. 3578 μg/L
Plasma half-life: c. 15 h
Volume of distribution: c. 131 L
Plasma protein binding: c. 95%
A single 600 mg dose given orally in combination with ritonavir 100 mg every 12 h increased the systemic exposure of darunavir approximately 14-fold. The relative bioavailability is 30% lower when administered with food in the presence of low-dose ritonavir. Distribution into human CSF, semen or breast milk has not yet been determined.
At least three oxidative metabolites, mediated predominantly through CYP3A4, have been identified in humans; all are at least 10-fold less active than the parent compound against HIV. Around 80% and 14% of the dose is found in the feces and urine, respectively. It should be used with caution in mild–moderate hepatic impairment and avoided in patients with more severe impairment.

Clinical Use

Treatment of HIV infection (in combination with other antiretroviral drugs)

부작용

In phase III studies the most common adverse events were diarrhea, nausea, headache and nasopharyngitis. Patients coinfected with hepatitis B or C did not have a higher incidence of adverse events.

다루나비르 준비 용품 및 원자재

원자재

준비 용품


다루나비르 공급 업체

글로벌( 145)공급 업체
공급자 전화 팩스 이메일 국가 제품 수 이점
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 21696 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20672 55
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 30001 58
Chemwill Asia Co.,Ltd.
86-21-51086038
86-21-51861608 chemwill_asia@126.com;sales@chemwill.com;chemwill@hotmail.com;chemwill@gmail.com CHINA 23980 58
BOC Sciences
1-631-619-7922
1-631-614-7828 inquiry@bocsci.com United States 20115 58
Chongqing Chemdad Co., Ltd
+86-13650506873
sales@chemdad.com CHINA 35440 58
Hubei widely chemical technology Co., Ltd. 027-83991130
027-83991130 1718093273@QQ.COM China 1894 58
Chembest Research Laboratories Limited +86(0)21-20908456
+86(0)21-58180499 sales@biochembest.com; market@biochembest.com China 5995 61
Chengdu Lanhao Biotechnology Co., Ltd. 15397625210
1813129729@qq.com China 110 58
Beijing Huikang Boyuan Chemical Tech Co., Ltd 010-68862197
010-68882204 bjhkby@126.com China 100 61

Copyright 2019 © ChemicalBook. All rights reserved